Gabapentin Capsule (Pregabalin)
Pregabalin 150mg
Hard capsule · Prescription medication
Austin Pharmaceutical Co., Ltd.
MFDS item code 201109312 · Approved 2011.10.31
This product's status changed to Expired on 2023.10.01. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of partial-onset seizures
This medication is used in adults to treat peripheral and central neuropathic pain. It is also utilized as an adjunctive treatment to control partial seizures in patients with epilepsy. Additionally, it is effective in alleviating symptoms of fibromyalgia. These benefits help in managing nerve-related pain and seizures.
This medicine is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Because this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In consideration of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, when discontinuing this medicine, it should be withdrawn gradually over a period of at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Because the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the method of administration. b: The supplemental dose refers to a dose administered as a single additional dose. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 to 17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behaviors, so close monitoring for depression or mood changes is necessary during treatment. Individuals allergic to pregabalin or any components of this medication should not take it. Patients with lactose intolerance or certain genetic metabolic disorders should also avoid this medication. Diabetic patients may require adjustments to their blood sugar control medications due to weight gain. If symptoms of angioedema occur, discontinue the medication immediately and consult a healthcare provider. Elderly patients should be cautious due to the risk of falls and injury from dizziness or drowsiness. This medication may cause changes in vision, such as blurred vision, so any unusual symptoms should be reported. Withdrawal symptoms such as insomnia, headache, and anxiety may occur upon abrupt discontinuation, so gradual tapering is advised. Since there is a potential for drug abuse or dependence, strict adherence to healthcare provider instructions is necessary during use. Patients with impaired kidney function may need dose adjustments. Caution is advised for patients with heart disease when taking this medication. Combining this drug with other CNS depressants may increase the risks of drowsiness or respiratory depression. Pregnant women should avoid this medication due to the risk of fetal malformations, and women of childbearing potential should use effective contraception. Breastfeeding women should consider discontinuing breastfeeding or switching medications since this drug may pass into breast milk. There is a risk of dizziness and drowsiness affecting the ability to drive or operate machinery safely. Severe skin reactions may rarely occur, so discontinue use immediately if rash or redness develops. Overdose may result in confusion, drowsiness, seizures, and may require treatments such as dialysis. This medication should be kept out of reach of children and should not be transferred to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. The storage temperature should be maintained at room temperature between 1 to 30 degrees Celsius. This helps preserve the drug's efficacy and safety over a long period.
A hard capsule with a white or off-white powder inside, with a white upper part and a white lower part.
30 capsules per bottle, 60 capsules per bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Pregabalin 150mg
Hard capsule · Prescription medication
Austin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.